EUVIMEDEUVIMED entdecken
Crossref

Antibiotic Prophylaxis of Transrectal Biopsy of the Prostate: A Plea for Fosfomycin

Philipp Julian Spachmann, Daniel Witt, Johannes Breyer, Stefan Denzinger, Maximilian Burger, Daniel Claudius Vergho, Wolfgang Otto, Marco Julius Schnabel

Urologia Internationalis · 2024

DOI: 10.1159/000541798 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Urologia Internationalis, 2024. Verfasst von Philipp Julian Spachmann und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departement of Urology, Caritas St. Josef Medical Center Regensburg, University of Regensburg, Regensburg, Germany. Hauptthemen laut MEDLINE: Fosfomycin, Antibiotic Prophylaxis, Prostate, Anti-Bacterial Agents. Die Arbeit nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

According to guidelines, transrectal random biopsy of the prostate (TRBP) is performed under antibiotic prophylaxis (AP). Fosfomycin-trometamol (FOS) is not approved in Germany, but TRBP as indication was listed in the product information falsely. The aim was to investigate infectious complications of TRBP under FOS as a single dose.

Methods

All TRBPs under FOS 3,000 mg as a single dose between July 1, 2020, and June 30, 2021, at a university institution were recorded. 357 patients (41–85 years old, median 66) were included. 243 received first TRBP, 321 TRBP were MRI-fusionated. 10–22 cores were taken (median 14). Prostate-specific antigen (PSA) was 0.1–1224 ng/mL (median 7.7 ng/mL), prostate volume 5–263 mL (median 50 mL). Analysis was performed using Chi square test or Fisher’s exact test, Mann-Whitney U test, and t test.

Results

Four patients suffered an infection (1.1%), without significant difference according to age (p = 0.849), PSA (p = 0.957), number of cores (p = 0.905), and increase in volume (p = 0.456). Limiting is the retrospective character.

Conclusion

The complication rate was 1.1%, and FOS single dose therefore represents sufficient AP for TRBP in this collective. FOS as a single dose should be reevaluated in a prospective study to obtain approval in Germany for this indication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FosfomycinAntibiotic ProphylaxisProstateAnti-Bacterial AgentsProstatic NeoplasmsHumansMaleAgedMiddle AgedAged, 80 and overAdultRetrospective StudiesImage-Guided BiopsyRectum

Stichwörter der Autor:innen

Antibiotic prophylaxisAntibiotic stewardshipFosfomycinInfectious complicationsTransrectal prostate biopsy

Substanzen

FosfomycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Departement of Urology, Caritas St. Josef Medical Center Regensburg, University of Regensburg, Regensburg, Germany.
  • Urologie Landau Isar and Urologie Plattling, Plattling, Germany.

Zitieren

APA

Spachmann, P. J., Witt, D., Breyer, J., Denzinger, S., Burger, M., Vergho, D. C., Otto, W., & Schnabel, M. J. (2024). Antibiotic Prophylaxis of Transrectal Biopsy of the Prostate: A Plea for Fosfomycin. Urologia Internationalis. https://doi.org/10.1159/000541798

Vancouver

Spachmann PJ, Witt D, Breyer J, Denzinger S, Burger M, Vergho DC, et al. Antibiotic Prophylaxis of Transrectal Biopsy of the Prostate: A Plea for Fosfomycin. Urologia Internationalis. 2024. doi:10.1159/000541798

BibTeX
@article{Spachmann2024,
  author = {Spachmann, Philipp Julian and Witt, Daniel and Breyer, Johannes and Denzinger, Stefan and Burger, Maximilian and Vergho, Daniel Claudius and Otto, Wolfgang and Schnabel, Marco Julius},
  title = {Antibiotic Prophylaxis of Transrectal Biopsy of the Prostate: A Plea for Fosfomycin},
  journal = {Urologia Internationalis},
  year = {2024},
  doi = {10.1159/000541798}
}
Kostenlos starten →